Latest news with #OndansetronOralFilm
Business Standard
10-07-2025
- Business
- Business Standard
Shilpa Medicare gains on receiving SFDA GMP certification for Bengaluru facility
Shilpa Medicare rose 1.73% to Rs 862 after the company announced that its Unit VI facility in Dabaspet, Bengaluru, Karnataka, has received Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA). The certification follows an on-site inspection conducted from 18 February to 20 February 2025. It was a full GMP inspection of the entire facility, with a specific focus on the Ondansetron Oral Film drug product. Notably, the inspection concluded with zero observations. Shilpa Medicares Unit VI is engaged in the manufacturing, testing, storage, and release of finished dosage forms, specifically oral films and transdermal patches. The facility currently supplies oral films to markets including the United States, Australia, and other emerging countries.
Business Standard
10-07-2025
- Health
- Business Standard
Shilpa Medicare's Unit VI facility receives SFDA, Saudi Arabia GMP certification
Shilpa Medicare's Unit VI facility, located at Dabaspet, Bengaluru, Karnataka, has received Saudi Food and Drug Authority (SFDA), Saudi Arabia, GMP certification. This follows the on-site inspection of this Site from 18 - 20th Feb 2025. This was a full GMP inspection of entire facility with specific focus on Ondansetron Oral Film drug product. The inspection was closed with ZERO observations. This facility of Shilpa Medicare Ltd is engaged in the manufacture, testing, storage and release of finished dosage forms in the category of Oral Films and Transdermal Patches. Oral Films are currently being supplied from this Site to US, Australia and other Emerging countries. The Site is approved by European Medicine Agency, Europe following a recent inspection by Finnish regulators.
